HolderBook

Diag Capital Management, LP

Reported holdings as of Q4 2018, from 1 quarterly filings.

This filer last reported in Q4 2018; the most recent quarter on file across all filers is Q2 2026. Firms that restructure stop filing under one CIK and start under another, so a successor entity may hold these positions now under a similar name.

CIK
1687807
Reported value
$87.4M
Positions
40
Top 10 weight
50.2%
Filed
2019-02-14
Days after quarter end
45

Holdings

SecurityTickerValue SharesWeightWeight change Held Change
BAXTER INTL INCBAX$5.7M85,9336.47%-newFIRST
ATHENEX INCATNX$5.4M429,0466.23%-newFIRST
ZIMMER BIOMET HOLDINGS INCZBH$4.9M47,6845.66%-newFIRST
ABBVIE INCABBV$4.6M50,4205.32%-newFIRST
INCYTE CORPINCY$4.6M72,1965.25%-newFIRST
QUANTERIX CORPQTRX$4.1M223,9494.69%-newFIRST
CELGENE CORPCELG$4.0M63,1594.63%-newFIRST
AMGEN INCAMGN$3.9M20,1104.48%-newFIRST
MEDTRONIC PLCMDT$3.3M36,1803.76%-newFIRST
QUOTIENT LTDQTNT$3.2M526,9323.69%-newFIRST
PCRX 3.25 2/19$3.2M74,5023.67%-newDEBT
TAKEDA PHARMACEUTICAL CO LTDTAK$3.0M177,2603.41%-newFIRST
ABBOTT LABORATORIESABT$2.8M38,5853.19%-newFIRST
ZAI LAB LTDZLAB$2.8M120,0923.19%-newFIRST
MYLAN N VMYL$2.7M99,4103.12%-newFIRST
POLARITYTE INCPTE$2.5M182,8332.82%-newFIRST
VIEWRAY INCVRAYQ$2.4M397,3752.76%-newFIRST
REGENERON PHARMACEUTICALSREGN$2.2M5,7922.47%-newFIRST
TEVA PHARMACEUTICAL INDS LTDTEVA$2.2M139,5312.46%-newFIRST
AKORN INCAKRXQ$2.1M634,0462.46%-newFIRST
HAEMONETICS CORP MASSHAE$2.1M21,2202.43%-newFIRST
ARGENX SEARGX$1.6M16,7121.84%-newFIRST
BIOHAVEN PHARMACTL HLDG CO LBHVNXXXX$1.4M38,3191.62%-newFIRST
MERIT MED SYS INCMMSI$1.4M25,0921.60%-newFIRST
SANOFI SASNY$1.3M30,2401.50%-newFIRST
GW PHARMACEUTICALS PLCGWPH$1.3M13,4601.50%-newFIRST
LIVANOVA PLCLIVN$1.1M11,9741.25%-newFIRST
MOLECULAR TEMPLATES INCMTEM$985.0K243,8391.13%-newFIRST
FOAMIX PHARMACEUTICALS LTDFOMX$960.0K146,4321.10%-newFIRST
VERRICA PHARMACEUTICALS INCVRCA$937.0K114,9471.07%-newFIRST
NEUROCRINE BIOSCIENCES INCNBIX$876.0K12,2661.00%-newFIRST
DENTSPLY SIRONA INCXRAY$757.0K20,3470.87%-newFIRST
AXONICS INCAXNX$702.0K46,4850.80%-newFIRST
ARYA SCIENCES ACQUISITION COARYAU$522.0K50,5000.60%-newFIRST
ADMA BIOLOGICS INCADMA$435.0K182,1000.50%-newFIRST
MADRIGAL PHARMACEUTICALS INCMDGL$326.0K2,8900.37%-newFIRST
ARVINAS INCARVN$311.0K24,2100.36%-newFIRST
NOVAVAX INC$286.0K155,3200.33%-newDEBT
NEOS THERAPEUTICS INCNEOS$278.0K168,6420.32%-newFIRST
ANAPTYSBIO INCANAB$95.0K1,4930.11%-newFIRST

By sector

Industry comes from the SIC code on each company's own SEC filings, which is self-reported and sometimes out of date. Derivative exposure is counted with the shares. Securities the SEC assigns no industry - funds, trusts, foreign issues - are shown as not classified rather than dropped.

Biotech & Pharma 41.2%Medical Devices 22.0%Not classified 36.8%
 
SectorValueShare
Biotech & Pharma$36.0M41.2%
Medical Devices$19.3M22.0%
Not classified$32.1M36.8%

Quarter by quarter

QuarterValuePositions NewAddedTrimmed ExitedTop 10 Days to file
Q4 2018$87.4M40000050.2%45

Rows marked UNVERIFIED ID, PLACEHOLDER ID, TICKER AS ID or NON-CUSIP ID carry an identifier that is not a valid CUSIP. They are shown because the filer reported that money, but treat the security named with caution - hover the chip for what is wrong with it, and see the methodology.

Held counts consecutive filings in which this manager reported the position, and can reach further back than the quarters listed above: the tabs begin at Q4 2018 because earlier coverage is too sparse to describe a market, but tenure is counted over every filing we hold, some reaching to 2007. A position sold and later rebought starts again from one.

Weight change is the shift in this position's share of the whole book, in percentage points. It is the more useful column: when money flows into or out of a broad fund, almost every holding is bought or sold at once, so added and trimmed largely track flows. A weight that rose while the book shrank is a decision. Both compare with the previous quarter this filer reported, not the previous calendar quarter.